CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc. Common Stock (CRGX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
crgx · stock forecast · 7 analysts (3M) · FMP · updated Aug 19, 2025
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Hold
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$34.00
Consensus
$23.00
+414.5% upside
Low
$7.00
Median: $28 · Last Close: $4.47
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$23.00
414.5% upside
High Target
$34
660.6%
Low Target
$7
56.6%
Current Price
$4.47
as of today
Based on analyst price targets, the CRGX stock price prediction for the next 12 months ranges from $7 to $34. The consensus CRGX price forecast of $23.00 implies 414.5% upside from the current price of $4.47.
Short-Term Price Prediction
RangingAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $4.47 | ↓ 0.00% |
1-day model range: $4.47–$4.47. Peak: $4.47 (-0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRGX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-07-08 | Jefferies | Maintains | Hold→Hold |
| 2025-01-30 | JP Morgan | Downgrade ↓ | Overweight→Underweight |
| 2025-01-30 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-01-30 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-01-30 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2025-01-30 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2025-01-30 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2025-01-30 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2024-11-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-13 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on CARGO Therapeutics, Inc. Common Stock (CRGX) stock. Of the recent 14 rating actions, 0 were upgrades and 7 were downgrades. 7 analysts currently cover CRGX.
Analyst Recommendation Trends
CRGX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 99.7% YoY
Revenue Next Year
$2M
↑ 229.6% YoY
EPS This Year
$-3.38
EPS Next Year
$-1.52
↓ 55.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRGX EPS of $-3.38 for the current fiscal year, based on estimates from 3 analysts. The CRGX revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CRGX stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRGX price target is $23.00 (+414.5% upside), with an analyst consensus of Hold.
The CRGX short-term stock prediction for tomorrow is $4.47 (-0.00%).
CARGO Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker CRGX. The CRGX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 0% of covering analysts.
Frequently asked questions
CRGX forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month CRGX price target is $23.00, with a high forecast of $34.00 and a low of $7.00. The median price target is shown in the chart above when available. This implies +414.5% potential upside from the current price of $4.47.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.